The Catalyst

Archive

05.12.14 | By Kristin Van Goor

Using new authority granted by the Food and Drug Administration Safety and Innovation Act (FDASIA), the Food and Drug Administration (FDA) issued d

05.09.14 | By Kaelan Hollon

Biopharmaceutical innovators work every day to build a robust pipeline and develop new medicines that help patients cope with some of the most debilitating diseases. This week, we released a new Medicines in Development report on mental health disorders that discussed a number of new approaches being pursued in order to treat these conditions. Currently, an estimated 61.5 million Americans suffer from mental illness, or one in every four U.S.

05.07.14 | By Jennifer Wall

So often the value of medicines gets lost in media reports when the focus is almost exclusively on cost.

Are we as a society willing to accept the fact that medicines, while not always inexpensive, provide great return on value because a child’s life has been saved or a friend was able to beat cancer? 

05.07.14 | By John Castellani

Each year at the National Prescription Drug Abuse Summit, discussions take place regarding the latest resources and tools for states, pharmacists, physicians, and law enforcement to use in combating the misuse and abuse of prescription medicines.

05.01.14 | By Jay Taylor

Yesterday’s release of the Special 301 report by the Office of the United States Trade Representative (USTR) once again underscores the challenges faced by innovators when confronted with deteriorating protections for intellectual property across the globe.

Pages